International Clinical Trial: Prospective, Multicenter, Single-Arm, Phase ? Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer

Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07314619) titled 'Prospective, Multicenter, Single-Arm, Phase ? Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer' on Dec. 18, 2025.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: The First Affiliated Hospital of Zhengzhou University

Condition: Platinum-resistant Recurrent Ovarian Cancer (PROC)

Intervention: Drug: Sacituzumab Tirumotecan Combined with Bevacizumab

Recruitment Status: Not recruiting

Phase: Phas...